Newsfeeds - Spark Newswire

2 minute read

Analyzing Gilead Sciences’s Short Interest

Today, 6:12 AM

Gilead Sciences's (NASDAQ:GILD) short percent of float has fallen 15.15% since its last report. The company recently reported that it has 17.56 million shares sold short, which is 1.4% of all regular shares that are available for trading.

GILD

1 minute read

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says

By Vandana Singh

Today, 6:12 AM

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has…

AZN

1 minute read

Why Is Gilead Sciences Stock Sliding Tuesday?

By Adam Eckert

Today, 6:12 AM

Gilead Sciences Inc (NASDAQ: GILD) shares are trading lower Tuesday after the company reported results from its Phase 2 non-small

GILD

4 minute read

Gilead Sciences Announces Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared To Anti-PD1 Alone In Phase 2 Non-Small Cell Lung Cancer Study

By Michael Horton

Today, 6:12 AM

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung

GILD

1 minute read

B of A Securities Reinstates Neutral on Gilead Sciences, Announces $85 Price Target

By Benzinga Newsdesk

Today, 6:12 AM

B of A Securities analyst Geoff Meacham reinstates Gilead Sciences (NASDAQ:GILD) with a Neutral and announces $85 price target.

GILD

4 minute read

Events
News

Gilead’s Kites Announced Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Yescarta CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma at ASH 2022

By Charles Gross

Today, 6:12 AM

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL).

GILD

3 minute read

Events
News

Gilead’s Kite Announced Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis at ASH 2022

By Charles Gross

Today, 6:12 AM

Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion ("vein-to-vein" time) for Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory (R/R

GILD

1 minute read

Gilead’s Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate

By Vandana Singh

Today, 6:12 AM

Kite, a Gilead Sciences Inc company (NASDAQ:GILD), announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc’s (NASDAQ:ACLX) lead late-stage product candidate, CART-ddBCMA,…

ACLX

1 minute read

ImmunoGen Announces Clinical Collaboration With Gilead To Evaluate Pivekimab Sunirine In Combination With Magrolimab In Relapsed/Refractory Acute Myeloid Leukemia

By Benzinga Newsdesk

Today, 6:12 AM

Collaboration to Explore Potential of Complementary Mechanisms of Action for Novel Doublet ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of

GILD

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

Today, 6:12 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

BDX